CUE-102
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Glioblastoma
Conditions
Recurrent Glioblastoma, Glioblastoma, Glioma, Malignant
Trial Timeline
Jul 30, 2025 → Jan 31, 2028
NCT ID
NCT06917885About CUE-102
CUE-102 is a phase 1 stage product being developed by Cue Biopharma for Recurrent Glioblastoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06917885. Target conditions include Recurrent Glioblastoma, Glioblastoma, Glioma, Malignant.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06917885 | Phase 1 | Recruiting |
| NCT05360680 | Phase 1 | Completed |
Competing Products
20 competing products in Recurrent Glioblastoma